Minocycline hydrochloride (MH), a semi-synthetic tetracycline derivative, is a clinically
available antibiotic and anti-inflammatory drug that also exhibits potent neuroprotective
activities. It has been shown to target multiple secondary injury mechanisms in spinal cord
injury, via its anti-inflammatory, anti-oxidant, and anti-apoptotic properties. The secondary
injury mechanisms that MH can potentially target include inflammation, free radicals and
oxidative stress, glutamate excitotoxicity, calcium influx, mitochondrial dysfunction, ischemia …